NeuBase Therapeutics Inc
NBSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.42M
Close$
$2.97
684.9% upside
Current Fair Value
684.9% upsideUndervalued by 684.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.42 Million |
|---|---|
| Enterprise Value | $-5,354,907.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-21.08 |
| Beta | 0.95 |
| Outstanding Shares | 2,758 |
Return
| Return on Equity | -156.66% |
|---|---|
| Return on Assets | -76.87% |
| Return on Invested Capital | -119.56% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.02 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.32 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -1.08 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NeuBase Therapeutics Inc
CEO: Dietrich Stephan